# C4 Therapeutics, Inc.: overview CCCC · Nasdaq · CIK 1662579 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cccc.md) · [Financials](/companies/cccc/financials.md) · [Filings](/companies/cccc/filings.md) · [Insiders](/companies/cccc/insiders.md) Latest reported revenue: [$6.6m](/filings/0001628280-26-055494.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-055494). ## Last eight quarters | Line item | Unit | Q1 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [15.4](/filings/0001628280-25-049854.md) | [5.2 d](/filings/0001628280-26-012000.md) | [7.2](/filings/0001628280-26-033865.md) | [6.5](/filings/0001628280-26-055494.md) | [11.2](/filings/0001628280-25-049854.md) | [11.0 d](/filings/0001628280-26-012000.md) | [6.2](/filings/0001628280-26-033865.md) | [6.6](/filings/0001628280-26-055494.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(183.9%)](/filings/0001628280-25-049854.md) | [(728.4%) d](/filings/0001628280-26-012000.md) | [(402.9%)](/filings/0001628280-26-033865.md) | [(441.0%)](/filings/0001628280-26-055494.md) | [(306.4%)](/filings/0001628280-25-049854.md) | [(210.1%) d](/filings/0001628280-26-012000.md) | [(451.6%)](/filings/0001628280-26-033865.md) | [(397.9%)](/filings/0001628280-26-055494.md) | | Net margin | % | [(160.6%)](/filings/0001628280-25-049854.md) | [(667.8%) d](/filings/0001628280-26-012000.md) | [(363.7%)](/filings/0001628280-26-055494.md) | [(402.6%)](/filings/0001628280-26-055494.md) | [(286.4%)](/filings/0001628280-25-049854.md) | [(186.0%) d](/filings/0001628280-26-012000.md) | [(408.5%)](/filings/0001628280-26-055494.md) | [(355.9%)](/filings/0001628280-26-055494.md) | | Diluted EPS | $ per share | [(0.35)](/filings/0001628280-25-049854.md) | not reported | [(0.37)](/filings/0001628280-26-033865.md) | [(0.37)](/filings/0001628280-26-055494.md) | [(0.44)](/filings/0001628280-25-049854.md) | not reported | [(0.20)](/filings/0001628280-26-033865.md) | [(0.18)](/filings/0001628280-26-055494.md) | | Free cash flow | $m | [(24.1) d](/filings/0001628280-25-049854.md) | [(17.9) d](/filings/0001628280-26-012000.md) | [(33.3)](/filings/0001628280-26-033865.md) | [(12.2) d](/filings/0001628280-26-055494.md) | [(31.6) d](/filings/0001628280-25-049854.md) | [(22.2) d](/filings/0001628280-26-012000.md) | [(30.0)](/filings/0001628280-26-033865.md) | [(1.6) d](/filings/0001628280-26-055494.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [45.8](/filings/0001628280-23-004711.md) | [31.1](/filings/0001628280-24-006144.md) | [20.8](/filings/0001628280-25-008433.md) | [35.6](/filings/0001628280-26-012000.md) | [35.9](/filings/0001628280-26-012000.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(179.4%)](/filings/0001628280-23-004711.md) | [(416.6%)](/filings/0001628280-24-006144.md) | [(669.8%)](/filings/0001628280-25-008433.md) | [(336.1%)](/filings/0001628280-26-012000.md) | [(320.5%)](/filings/0001628280-26-012000.md) | | Net margin | % | [(183.2%)](/filings/0001628280-23-004711.md) | [(412.2%)](/filings/0001628280-24-006144.md) | [(638.3%)](/filings/0001628280-25-008433.md) | [(296.0%)](/filings/0001628280-26-012000.md) | [(292.1%)](/filings/0001628280-26-012000.md) | | Diluted EPS | $ per share | [(1.82)](/filings/0001628280-23-004711.md) | [(2.62)](/filings/0001628280-24-006144.md) | [(2.67)](/filings/0001628280-25-008433.md) | [(1.52)](/filings/0001628280-26-012000.md) | [(1.27)](/filings/0001628280-26-012000.md) | | Free cash flow | $m | [(88.2)](/filings/0001628280-23-004711.md) | [(111)](/filings/0001628280-24-006144.md) | [(109)](/filings/0001628280-25-008433.md) | [(65.3)](/filings/0001628280-26-012000.md) | [(99.3)](/filings/0001628280-26-012000.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cccc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $41.4m | 8,867,338 | | Reduced −205,062 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $37.4m | 8,000,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $36.9m | 7,896,718 | | Added +5,848,192 | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $34.2m | 7,326,691 | | Added +327,789 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $33.6m | 7,200,000 | | Added +4,950,000 | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $33.5m | 7,171,910 | | Unchanged | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $20.7m | 4,747,424 | | Added +1,524,370 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $20.6m | 4,417,731 | | Added +555,879 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $19.6m | 4,187,580 | | Added +1,676,565 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $16.5m | 3,530,991 | | Added +1,143,613 | ## Recent filings [All 536 filings](/companies/cccc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-25 | 11:04 ET | [8-K](/filings/0001628280-26-063497.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-063497 | | 2026-08-11 | 11:29 ET | [10-Q](/filings/0001628280-26-055494.md) | Quarterly report, period 2026-06-30 | 0001628280-26-055494 | | 2026-08-11 | 11:14 ET | [8-K](/filings/0001628280-26-055490.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-055490 | | 2026-06-24 | 20:22 ET | [8-K](/filings/0001628280-26-045194.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-045194 | | 2026-06-11 | 11:04 ET | [8-K](/filings/0001628280-26-042365.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-042365 | | 2026-05-15 | 20:03 ET | [8-K](/filings/0001628280-26-035542.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-035542 | | 2026-05-12 | 11:07 ET | [10-Q](/filings/0001628280-26-033865.md) | Quarterly report, period 2026-03-31 | 0001628280-26-033865 | | 2026-05-12 | 11:05 ET | [8-K](/filings/0001628280-26-033861.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-033861 | | 2026-04-29 | 11:00 ET | [DEF 14A](/filings/0001628280-26-028104.md) | Proxy statement, period 2026-04-29 | 0001628280-26-028104 | | 2026-04-10 | 11:17 ET | [8-K](/filings/0001628280-26-024583.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001628280-26-024583 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012000.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/93930402-b362-45fd-b4cc-e5dbb19dfb0c) ## About the filer - CIK: 1662579 - Tickers: CCCC - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.